| A VWF independent recombinant DNA-derived, FVIII concentrate is being developed by Bioverativ, a Sanofi company, and Sobi for the treatment of hemophilia A. |
| Received its first approval on 22 February 2023 in the USA. |
| Approved for use in adults and children with hemophilia A (congenital FVIII deficiency) for: routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; perioperative management of bleeding. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.